# Linc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/linc).

## Overview

Linc AB is a Stockholm-based investment company focused on Nordic life science businesses. It invests in both private and listed companies, with a portfolio centered on product-oriented pharmaceutical and medical technology businesses that can scale internationally.

## Products & services

• Equity investments in Nordic life science companies
• Investments in private and listed portfolio companies
• Capital support for clinical development programs
• Portfolio management and value creation through ownership stakes
• ETF and listed-share exposure to medtech and pharma

- **Direct portfolio investments** (70%) — Ownership stakes in private and listed life science companies held for value appreciation.
- **Capital commitments** (15%) — Committed follow-on funding for portfolio companies advancing clinical or commercial milestones.
- **Listed securities and ETF exposure** (15%) — Public market positions in medtech and pharmaceutical companies through shares and ETFs.

- Equity investments in Nordic life science companies
- Investments in private and listed portfolio companies
- Capital support for clinical development programs
- Portfolio management and value creation through ownership stakes
- ETF and listed-share exposure to medtech and pharma

## Customers

Linc does not sell products to end customers; its capital is deployed to portfolio companies in the life science sector. The main counterparties are Nordic biotech, pharma, and medtech businesses that need funding for research, clinical trials, commercialization, or acquisitions. Value creation depends on those companies reaching technical, regulatory, and market milestones that increase portfolio value.

- **Clinical-stage biotech companies** (primary) — Companies such as Gesynta Pharma and Oncorena that need staged funding for trials and development milestones.
- **Commercial medtech companies** (primary) — Businesses like Stille and OssDsign that use capital to expand operations, supply chains, and product reach.
- **Listed life science issuers** (secondary) — Publicly traded holdings where Linc participates as a long-term owner and benefits from market re-rating.
- **ETF and index exposures** (secondary) — Broader medtech and pharma market exposure used to diversify the portfolio beyond single-name risk.

- Nordic biotech companies funding drug development
- Medical technology firms financing commercialization and growth
- Listed life science companies seeking strategic capital
- Clinical-stage companies needing milestone-based funding
- Portfolio companies that benefit from active ownership and support

## Geography

Linc is headquartered in Stockholm and operates as a Nordic investment company. Its portfolio is concentrated in the Nordic life science ecosystem, while many underlying holdings target global markets through pharmaceuticals and medical devices. This creates exposure to both Scandinavian capital markets and international healthcare demand.

- **Nordics** (100%) — Investment focus and portfolio concentration are primarily Nordic.

- Headquartered in Stockholm, Sweden
- Core investment focus is the Nordic life science market
- Portfolio companies often sell into global healthcare markets
- Listed holdings add exposure to Nordic stock markets
- Currency moves such as SEK/USD can affect reported value

## Strategy

Linc’s strategy is to back product-oriented life science companies with global potential and to hold stakes long enough for clinical, regulatory, and commercial value to emerge. It also uses a mix of private investments, listed holdings, and selective follow-on commitments to build a diversified portfolio across the Nordic healthcare ecosystem.

- **Back companies with clear product and market potential** (medium-term) — The portfolio depends on scientific and commercial milestones translating into valuation gains.
- **Maintain diversified exposure across private and listed assets** (short-term) — Diversification reduces single-asset volatility in a sector where outcomes are binary and timing is uncertain.
- **Preserve flexibility for follow-on investments** (short-term) — Capital commitments are often released in tranches tied to development milestones.

- Focus on product-oriented life science businesses with global potential
- Invest across private and public companies to diversify risk
- Support portfolio companies through milestone-based follow-on funding
- Use listed holdings and ETFs to broaden sector exposure
- Capture value from clinical progress, approvals, and commercial scaling

## Risks

Linc’s results are driven by fair value changes in a concentrated portfolio, so valuation swings in a few holdings can materially affect reported performance. The business is also exposed to clinical, regulatory, and financing risk in underlying portfolio companies, as well as market risk from listed biotech and medtech shares and currency movements.

- **Fair value volatility in portfolio holdings** [high] — Reported performance depends heavily on mark-to-market changes in listed and unlisted investments.
- **Clinical and regulatory failure risk** [high] — Many holdings depend on trial outcomes, approvals, and development milestones.
- **Market risk in listed life science shares** [high] — Public holdings can reprice quickly on sector sentiment, financing events, or trial news.
- **Currency exposure** [medium] — Some portfolio exposure is denominated in USD and other currencies, affecting returns in SEK.
- **Tax on non-qualifying holdings** [medium] — Certain direct holdings may be taxable, creating volatility in net result from unrealized gains.

- Portfolio value can swing sharply with biotech and medtech revaluations
- Clinical trial setbacks can reduce the value of private holdings
- Listed holdings add market volatility and sentiment risk
- SEK/USD moves affect international portfolio exposure
- Tax treatment of holdings can create earnings volatility

## Accounting

Linc’s reported numbers are dominated by fair value accounting for portfolio investments, so unrealized gains and losses can move earnings materially without cash changing hands. The company also has milestone-based investment commitments, tax effects on non-qualifying holdings, and valuation judgments for unlisted assets that require estimation and can change as new information arrives.

- **Fair value measurement of portfolio investments** — Large unrealized gains or losses can dominate quarterly results
- **Valuation of unlisted investments** — Estimation uncertainty can materially change NAV
- **Tax on non-qualifying shareholdings** — Can create period-specific tax charges unrelated to cash flow
- **Investment commitments and tranches** — Affects future liquidity planning and capital allocation

- Fair value changes drive most reported profit and loss
- Unlisted holdings require valuation judgment and model inputs
- Milestone-based commitments affect future cash needs
- Tax treatment of holdings can create volatile quarterly charges
- Listed positions are sensitive to market prices and FX

---

*Last updated: 2026-08-11T04:04:53.953160+00:00*